CDK4 and breast carcinoma: These encouraging results prompted the phase III CAPItello-291 trial, which looked into the safety and effectiveness of this joint therapy for patients with AI-resistant advanced HR+/HER2− breast cancer, particularly those who had undergone CDK4/6 inhibitors treatment before.